Efficacy of intracellular immune checkpoint-silenced DC vaccine

BACKGROUND. DC-based tumor vaccines have had limited clinical success thus far. SOCS1, a key inhibitor of inflammatory cytokine signaling, is an immune checkpoint regulator that limits DC immunopotency. METHODS. We generated a genetically modified DC (gmDC) vaccine to perform immunotherapy. The aden...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Danhong, Huang, Xue F., Hong, Bangxing, Song, Xiao-Tong, Hu, Liangding, Jiang, Min, Zhang, Bin, Ning, Hongmei, Li, Yuhang, Xu, Chen, Lou, Xiao, Li, Botao, Yu, Zhiyong, Hu, Jiangwei, Chen, Jianlin, Yang, Fan, Gao, Haiyan, Ding, Guoliang, Liao, Lianming, Rollins, Lisa, Jones, Lindsey, Chen, Si-Yi, Chen, Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2018
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821183/
https://www.ncbi.nlm.nih.gov/pubmed/29415891
http://dx.doi.org/10.1172/jci.insight.98368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821183/
https://www.ncbi.nlm.nih.gov/pubmed/29415891
http://dx.doi.org/10.1172/jci.insight.98368

Ejemplares similares